A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
New England Journal of Medicine · 08.02.2024 · 390 (6) · 497-509
DOI: 10.1056/nejmoa2309000 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 08.02.2024. Verfasst von Stephen A Harrison und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University,…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Pyridazines, Uracil. Die Arbeit wurde bisher 2150-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Madrigal Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health R…
ORCID-Profile: Jörn M Schattenberg, Rebecca Taub, Zobair Younossi, Sven Francque, Philip N Newsome, Nicolas Lanthier
Förderung
- Madrigal Pharmaceuticals
Zitieren
APA
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., …, & MAESTRO-NASH Investigators (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine, 390(6), 497-509. https://doi.org/10.1056/nejmoa2309000
Vancouver
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine. 2024;390(6):497-509. doi:10.1056/nejmoa2309000
BibTeX
@article{Harrison2024,
author = {Harrison, Stephen A and Bedossa, Pierre and Guy, Cynthia D and Schattenberg, Jörn M and Loomba, Rohit and Taub, Rebecca and Labriola, Dominic and Moussa, Sam E and Neff, Guy W and Rinella, Mary E and Anstee, Quentin M and Abdelmalek, Manal F and Younossi, Zobair and Baum, Seth J and Francque, Sven and Charlton, Michael R and Newsome, Philip N and Lanthier, Nicolas and Schiefke, Ingolf and Mangia, Alessandra and Pericàs, Juan M and Patil, Rashmee and Sanyal, Arun J and Noureddin, Mazen and Bansal, Meena B and Alkhouri, Naim and Castera, Laurent and Rudraraju, Madhavi and Ratziu, Vlad and MAESTRO-NASH Investigators, MAESTRO-NASH Investigators},
title = {A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {6},
pages = {497--509},
doi = {10.1056/nejmoa2309000}
}
EUVIMED